MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder

Phase 3
Terminated
Conditions
Bipolar Disorder
Interventions
Drug: Placebo
Drug: Ramelteon SL
First Posted Date
2011-11-09
Last Posted Date
2016-05-16
Lead Sponsor
Takeda
Target Recruit Count
642
Registration Number
NCT01467713

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

Phase 3
Terminated
Conditions
Acute Depressive Episode
Interventions
Drug: Ramelteon SL
Drug: Placebo
First Posted Date
2011-11-09
Last Posted Date
2016-05-16
Lead Sponsor
Takeda
Target Recruit Count
490
Registration Number
NCT01467700

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis

Phase 3
Completed
Conditions
Erosive Esophagitis
Interventions
Drug: TAK-438
Drug: Lansoprazole
First Posted Date
2011-10-25
Last Posted Date
2013-08-23
Lead Sponsor
Takeda
Target Recruit Count
607
Registration Number
NCT01459367

Efficacy and Safety of TAK-385 in the Treatment of Endometriosis

Phase 2
Completed
Conditions
Endometriosis
Interventions
Drug: Placebo
Drug: TAK-385
Drug: Leuprorelin acetate
First Posted Date
2011-10-24
Last Posted Date
2014-02-25
Lead Sponsor
Takeda
Target Recruit Count
487
Registration Number
NCT01458301

Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Pioglitazone
Drug: Placebo
First Posted Date
2011-10-20
Last Posted Date
2012-08-08
Lead Sponsor
Takeda
Target Recruit Count
61
Registration Number
NCT01456117

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
Drug: Fasiglifam
First Posted Date
2011-10-20
Last Posted Date
2016-04-05
Lead Sponsor
Takeda
Target Recruit Count
421
Registration Number
NCT01456195

Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes

Phase 3
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Alogliptin
Drug: Rapid-acting insulin secretagogue
First Posted Date
2011-10-20
Last Posted Date
2014-04-21
Lead Sponsor
Takeda
Target Recruit Count
67
Registration Number
NCT01456130

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Phase 3
Completed
Conditions
Gastric Ulcers
Duodenal Ulcers
Interventions
Drug: TAK-438
Drug: Lansoprazole
Drug: Placebo
First Posted Date
2011-10-20
Last Posted Date
2014-05-08
Lead Sponsor
Takeda
Target Recruit Count
406
Registration Number
NCT01456260

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Phase 3
Completed
Conditions
Gastric Ulcers
Duodenal Ulcers
Interventions
Drug: TAK-438
Drug: Lansoprazole
Drug: Placebo
First Posted Date
2011-10-20
Last Posted Date
2014-05-08
Lead Sponsor
Takeda
Target Recruit Count
439
Registration Number
NCT01456247

A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

Phase 3
Completed
Conditions
Essential Hypertension
Interventions
Drug: Azilsartan medoxomil - chlorthalidone
Drug: Azilsartan medoxomil/placebo
First Posted Date
2011-10-20
Last Posted Date
2014-04-23
Lead Sponsor
Takeda
Target Recruit Count
507
Registration Number
NCT01456169
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy